A recent Health Affairs blog post suggests the inclusion of more novel value elements in the assessment of COVID-19 drugs is necessary.
The blog post by Sachin Kamal-Bahl et al. offers a look at a number of non-traditional value elements, including fear of contagion, insurance and uncertainty, as well as the value of hope.
Louis Garrison, Sachin Kamal-Bahl and Adrian Towse identified the novel value elements in a paper published in 2017. An ISPOR task force later expanded upon the new elements.
“To incentivize product innovation at a level that recognizes its full value to patients and society, there is a clear need to move beyond the traditional cost per QALY approach and consider novel elements of value in the context of COVID-19,” the post states.
To read the full blog post, click here.